The FDA approved Stiolto Respimat for the once-daily maintenance treatment in patients with COPD as well as chronic bronchitis and emphysema, according to a Boehringer Ingelheim press release.Stiolto Respimat (tiotropium bromide and olodaterol) is a propellant-free, platform inhalation spray, intended to be used as a long-term, once-daily maintenance treatment of airflow obstruction, according to the release.
No comments:
Post a Comment